Additional caution or monitoring may be appropriate in research settings involving: Pregnancy- or lactation-related research models, where limited safety data is available Active cancer-, tumor-, or abnormal proliferative research models, where NAD-related and metabolic-signaling pathways may influence cellular-signaling mechanisms Cardiovascular- or uncontrolled-hypertension research models, where metabolic-pathway modulation may influence cardiovascular-related biomarkers in some experimental settings Thyroid-related or endocrine research models, where metabolic-pathway investigations may influence endocrine-related observations Diabetes- or glucose-regulation research models, where insulin- and glucose-related pathways may warrant closer monitoring in experimental settings Moderate to severe hepatic- or renal-impairment research models, where compound metabolism or clearance mechanisms may be altered Autoimmune- or inflammatory-response research models, where immune-metabolic signaling pathways may influence inflammatory-related biomarkers or cytokine observations Research conditions, dosage ranges, administration frequency, protocol duration, and concurrent compounds may influence tolerability observations across experimental settings
Additionally, 1,8-diMQ and 5-amino-1MQ showed little inhibition of COMT at maximal tested concentrations of 200 M (20% inhibition) and 600 M (10% inhibition), respectively, although no clear trend of concentration-dependent inhibition was observed
Immediately Either a one off injection or a booster course of 5 injections over two weeks 5 minutes (estimate) Possible headache, some slight itching, and some minor anxiety
It can also appear on the bowel, bladder, and in some cases on the lungs or skin
